TISIDB

Summary
Symbol	SEPT4
Name	septin 4
Aliases	CE5B3; hucep-7; hCDCREL-2; MART; bradeoin; septin-M; PNUTL2; peanut-like 2 (Drosophila); BRADEION; SEP4; CE5 ......
Chromosomal Location	17q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cytoplasm Cytoplasm, cytoskeleton Cell projection, cilium, flagellum Note=In platelets, found in areas surrounding alpha-granules. Found in the sperm annulus (PubMed:25588830). ; SUBCELLULAR LOCATION: Isoform ARTS: Mitochondrion. Nucleus. Note=While predominantly localized in the mitochondria under resting conditions, isoform ARTS translocates into the nucleus after TGF-beta treatment and apoptosis induction.
Domain	PF00735 Septin
Function	Filament-forming cytoskeletal GTPase (By similarity). May play a role in cytokinesis (Potential). Forms a filamentous structure with SEPT12, SEPT6, SEPT2 and probably SEPT4 at the sperm annulus which is required for the structural integrity and motility of the sperm tail during postmeiotic differentiation (PubMed:25588830). May play a role in platelet secretion. Isoform ARTS, but not the other isoforms, is required for the induction of cell death mediated by TGF-beta and by other apoptotic stimuli.

> Gene Ontology [ TOP ]
Biological Process	GO:0007281 germ cell development GO:0007283 spermatogenesis GO:0007286 spermatid development GO:0021700 developmental maturation GO:0022412 cellular process involved in reproduction in multicellular organism GO:0030382 sperm mitochondrion organization GO:0031396 regulation of protein ubiquitination GO:0031398 positive regulation of protein ubiquitination GO:0048232 male gamete generation GO:0048240 sperm capacitation GO:0048469 cell maturation GO:0048515 spermatid differentiation GO:0097193 intrinsic apoptotic signaling pathway GO:1903320 regulation of protein modification by small protein conjugation or removal GO:1903322 positive regulation of protein modification by small protein conjugation or removal GO:2001233 regulation of apoptotic signaling pathway GO:2001235 positive regulation of apoptotic signaling pathway GO:2001242 regulation of intrinsic apoptotic signaling pathway GO:2001244 positive regulation of intrinsic apoptotic signaling pathway
Molecular Function	GO:0003924 GTPase activity GO:0005525 GTP binding GO:0019001 guanyl nucleotide binding GO:0032561 guanyl ribonucleotide binding
Cellular Component	GO:0005929 cilium GO:0031514 motile cilium GO:0036126 sperm flagellum GO:0043209 myelin sheath GO:0044441 ciliary part GO:0097223 sperm part GO:0097227 sperm annulus

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04210 Apoptosis
Reactome	-

Summary
Symbol	SEPT4
Name	septin 4
Aliases	CE5B3; hucep-7; hCDCREL-2; MART; bradeoin; septin-M; PNUTL2; peanut-like 2 (Drosophila); BRADEION; SEP4; CE5 ......
Chromosomal Location	17q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between SEPT4 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between SEPT4 and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
24045181	Melanoma	Promote immunity (T cell function)	In melanoma studies, all MART-1-specific CD8(+) TILs upregulated CD137 expression after incubation with HLA-matched, MART-expressing cancer cells and antigen-specific effector function was restricted to the CD137(pos) subset in vitro.

Summary
Symbol	SEPT4
Name	septin 4
Aliases	CE5B3; hucep-7; hCDCREL-2; MART; bradeoin; septin-M; PNUTL2; peanut-like 2 (Drosophila); BRADEION; SEP4; CE5 ......
Chromosomal Location	17q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of SEPT4 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	SEPT4
Name	septin 4
Aliases	CE5B3; hucep-7; hCDCREL-2; MART; bradeoin; septin-M; PNUTL2; peanut-like 2 (Drosophila); BRADEION; SEP4; CE5 ......
Chromosomal Location	17q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of SEPT4 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.329	0.544
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.336	0.855
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.315	0.804
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	1
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	1
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	1
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.034	0.929
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.532	0.644
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.628	0.656
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	1.111	0.593
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.946	0.507
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.224	0.0495

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of SEPT4 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	2.7	1	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	3.4	0.3	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	SEPT4
Name	septin 4
Aliases	CE5B3; hucep-7; hCDCREL-2; MART; bradeoin; septin-M; PNUTL2; peanut-like 2 (Drosophila); BRADEION; SEP4; CE5 ......
Chromosomal Location	17q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SEPT4. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	SEPT4
Name	septin 4
Aliases	CE5B3; hucep-7; hCDCREL-2; MART; bradeoin; septin-M; PNUTL2; peanut-like 2 (Drosophila); BRADEION; SEP4; CE5 ......
Chromosomal Location	17q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SEPT4. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SEPT4. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	SEPT4
Name	septin 4
Aliases	CE5B3; hucep-7; hCDCREL-2; MART; bradeoin; septin-M; PNUTL2; peanut-like 2 (Drosophila); BRADEION; SEP4; CE5 ......
Chromosomal Location	17q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SEPT4. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	SEPT4
Name	septin 4
Aliases	CE5B3; hucep-7; hCDCREL-2; MART; bradeoin; septin-M; PNUTL2; peanut-like 2 (Drosophila); BRADEION; SEP4; CE5 ......
Chromosomal Location	17q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of SEPT4 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	SEPT4
Name	septin 4
Aliases	CE5B3; hucep-7; hCDCREL-2; MART; bradeoin; septin-M; PNUTL2; peanut-like 2 (Drosophila); BRADEION; SEP4; CE5 ......
Chromosomal Location	17q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between SEPT4 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	SEPT4
Name	septin 4
Aliases	CE5B3; hucep-7; hCDCREL-2; MART; bradeoin; septin-M; PNUTL2; peanut-like 2 (Drosophila); BRADEION; SEP4; CE5 ......
Chromosomal Location	17q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting SEPT4 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse SEPT4